Results 51 to 60 of about 6,351 (173)
Impact of Alzheimer's disease on sleep in adults with Down syndrome
Alzheimer's &Dementia, Volume 21, Issue 7, July 2025.Abstract INTRODUCTION Down syndrome (DS) is a genetic form of Alzheimer's disease (AD), with a high prevalence of sleep disorders, but data in adults with DS and dementia are lacking. We aim to assess sleep in adults with DS across the AD continuum. METHODS We studied 78 healthy controls and 229 adults with DS (154 asymptomatic, 25 with prodromal AD ...
Sandra Giménez +23 more
wiley +1 more source
Estratégia de proteção de patentes farmacêuticas: o caso do atazanavir
RECIIS, 2016 O alto custo dos medicamentos antirretrovirais (ARVs) justifica estudos sobre estratégias de patenteamento farmacêutico vis-à-vis à política pública brasileira de acesso universal aos ARVs.
Carla Cristina de Freitas da Silveira +2 more
doaj +1 more source
Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.Abstract INTRODUCTION Plasma phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non‐AD dementias in a large international ...
James D. Doecke +35 more
wiley +1 more source
Patentes Farmacêuticas e direito à saúde
Scientia Iuris, 2011 O presente trabalho tem por objetivo a análise do instituto das patentes de segundo uso médico, não expressamente regulamentado na ordem jurídica brasileira. Nesta tarefa, valer-se-á do marco teórico da Teoria do Direito como Integridade.
Gustavo Candian Filardi +1 more
doaj
La financiarización de las grandes empresas farmacéuticas
Revista Internacional de Sociología, 2020 En este artículo, empleamos un marco Vebleniano para analizar tres dimensiones de la financiarización corporativa: la expansión del balance, la creciente importancia de los activos intangibles y los crecientes niveles de pagos financieros.
Tobias J. Klinge +2 more
doaj +1 more source
Right of access to medicines as corollary of international action against illegal medical products [PDF]
, 2017 Se defiende abordar el problema de acceso a medicamentos seguros, combinando los discursos económico y humanista, que buscan proteger los derechos de propiedad intelectual frente a la falsificación de medicamentos, y al mismo tiempo hacer efectivo el ...
García San José, Daniel
core
Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome
Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.Abstract INTRODUCTION Synaptic dysfunction and loss are pathological hallmarks of neurodegenerative diseases. Neuronal pentraxin 2 (NPTX2), a presynaptic protein involved in synaptic plasticity, has been linked to cognitive decline in Alzheimer's disease (AD) and other neurodegenerative disorders.
Mathias Sauer +24 more
wiley +1 more source
Revista de Direito Sanitário, 2007 A introdução do art. 229-C à Lei de Propriedade Intelectual (Lei n. 9.279/96), pela Lei n. 10.196/01, condicionou a concessão de patentes farmacêuticas pelo Instituto Nacional de Propriedade Intelectual (INPI) à anuência prévia da Agência Nacional de ...
TOJAL, Sebastião Botto de Barros +1 more
doaj +1 more source
Society claims more ethical pharmaceutical market [PDF]
, 2014 Este documento presenta una aproximación a la problemática social que muestra el sector farmacéutico sobre falta de ética, competencia desleal, conflicto de intereses y perdida de vigencia de la visita médica todos relacionados con aspectos tales como ...
Usma León, Adriana María
core
Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.Abstract Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population‐based multimodal biomarker cohort studying AD's natural history and clinical trials in DS.
Laura Videla +54 more
wiley +1 more source